Oric Pharmaceuticals, Inc. (ORIC)

Oppenheimer and Cantor Fitzgerald issued positive ratings for ORIC's stock. ORIC announced the granting of inducement stock options and restricted stock units to a new non-executive employee. Ladenburg Thalmann initiated coverage with a "Buy" rating and a $15.0 price target. ORIC reported its second-quarter 2025 financial results and announced a strategic decision to reduce its investment in discovery research, leading to a 20% workforce reduction, extending the company's cash runway into the second half of 2028. HC Wainwright & Co. and J.P. Morgan issued "Buy" ratings. Guggenheim set a price target of $18.0 for ORIC's stock. CEO Jacob Chacko sold 125,000 shares of the company's stock. Weiss Ratings restated a "sell" rating on Oric Pharmaceuticals shares. ORIC Pharmaceuticals presented preclinical data on ORIC-944 at the EORTC-NCI-AACR International Conference. Simply Wall St reported on the promising preclinical results of ORIC-944 and noted strong share price returns in 2024.

As a clinical-stage biopharmaceutical company, Oric Pharmaceuticals, Inc. does not currently have commercialized products or services, therefore, there is no information available regarding demand seasonality for its products or services.

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that counteract resistance mechanisms in cancer, operating within the Health Technology sector. Its pipeline focuses on hormone-dependent cancers, precision oncology, and key tumor dependencies. Major product candidates include ORIC-944, a selective allosteric inhibitor of PRC2 being developed for prostate cancer and other solid tumors; ORIC-114, a brain-penetrant EGFR/HER2 exon 20 inhibitor designed for cancers with specific genetic mutations; ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being investigated for multiple myeloma and hormone receptor-positive breast cancer; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers, currently in preclinical studies.

Oric Pharmaceuticals, Inc. is headquartered in South San Francisco, California, with additional offices in San Diego, California.

Oric Pharmaceuticals, Inc.'s brand reputation is primarily tied to its scientific advancements, clinical trial results, and pipeline progress rather than traditional consumer brand perception.

The majority of Oric Pharmaceuticals, Inc.'s outstanding shares are owned by institutional investors, accounting for 60% to 95.1% of the company. Major institutional shareholders include Pfizer Inc., Nextech Invest AG, and BlackRock Inc. Insiders own approximately 5.6% of the company's shares. Recent insider trading activity includes sales by CEO Jacob Chacko and CFO Dominic Piscitelli, and purchases by Angie You.